Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Royal jelly, a secretion produced by honeybees, has attracted scientific interest for its potential neuroprotective effects, including possible benefits for Alzheimer's Disease (AD). Preclinical studies, largely conducted in vitro and in animal models, suggest royal jelly may exert beneficial effects through several mechanisms relevant to AD. These include antioxidative properties, anti-inflammatory actions, enhancement of neurogenesis, and modulation of cholinergic activity—an important pathway that is impaired in AD. Some studies have demonstrated that royal jelly can improve cognitive performance and reduce amyloid-beta deposition in rodent models of AD. Additionally, components of royal jelly such as 10-hydroxy-2-decenoic acid (10-HDA) have been investigated for their potential to promote neuronal survival and synaptic plasticity.

However, robust clinical data in humans are lacking. Only a few small-scale human trials or case studies exist, and these do not provide sufficient evidence to conclude efficacy or safety for AD patients. The majority of evidence supporting royal jelly's use in AD is preclinical or preliminary. No major clinical guidelines recommend royal jelly for Alzheimer's treatment. Thus, while there is a scientific rationale and some experimental support, the overall quality of evidence is low, and more rigorous human studies are needed to validate any therapeutic claims.

More about royal jelly
More about Alzheimer's Disease

Other ingredients used for Alzheimer's Disease

Other health conditions supported by royal jelly

Products containing royal jelly

Nature's Sunshine Elderberry D3fense
Nature's Sunshine Immune System